Compare Recursion Pharmaceuticals Inc (RXRX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snowflake Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Snowflake Inc trades at $331.89 (market cap $118.36B). The key difference: Snowflake Inc is far larger — about 63.6× Recursion Pharmaceuticals Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SNOW | |
|---|---|---|
Market Cap | $1.86B | $118.36B |
Sector | Health | Technology |
52-Week High | $6.79 | $356.47 |
52-Week Low | $2.84 | $121.11 |
Enterprise Value | $1.38B | $118.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Snowflake (SNOW) trades at $335.50, down 0.5% on the day, but maintains strong technical momentum with bullish moving averages and support at $331. The company demonstrates accelerating revenue growth, with Q2 2026 EPS beating expectations at $0.62 versus $0.45, and product revenue up 37% year-over-year. Recent news highlights AI-driven customer expansion and improved guidance, with the stock gaining 67% year-to-date in 2026.
Snowflake presents a growth-oriented investment case with robust AI adoption and enterprise expansion driving revenue acceleration. However, negative profitability metrics and elevated valuation multiples (P/S 21.25, P/B 55.06) pose significant risks. Analyst consensus remains strongly bullish with a $430 price target, but investors must weigh growth potential against persistent losses and competitive pressures in cloud analytics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
